Small Doses Muscle Relaxant in General Anesthesia

• Status: Recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study will be held to assess the effect of minimal dose muscle relaxant on postoperative pulmonary function. The time to extubation in minutes will be the primary outcome as a clinical indicator of the return of muscle power. The extubation time will be defined as the time from injecting the muscle relaxant reversing agent given when regain the train of four (TOF) ratio to 0.9 till removal of endotracheal tube.

Intraoperative surgical conditions will be assessed in the form of surgeon satisfaction and the need for more muscle relaxant boluses. Postoperative complications as desaturation (peripheral oxygen saturation (Spo2) less than 90%), the need for re-intubation or ventilation support will be recorded. Patient lung will be assessed using ultrasound-based lung aeration score. Also, the diaphragmatic and intercostal muscle function will be assessed in the early postoperative period. Immediate postoperative pulmonary function tests will be evaluated using simple spirometer. Patients will be followed up for 28 days for detection of pulmonary complications.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mansoura University
• Treatments: Atracurium

Criteria

Inclusion Criteria:

• adult patients

• aged from 20 to 50 years old

• scheduled for non-cardiothoracic surgery

• under general anesthesia

• in supine position

• after informed consent

Exclusion Criteria:

• American Society of Anesthesiologists (ASA) score more than 3

• suspected full stomach or who will undergo intervention expected to necessitate profound muscle relaxation or dressing interferes with ultrasound (US) probe positioning

• Lung parenchymatous disease

• renal disease

• hepatic disease

• neuromuscular disease

• electrolytes imbalanc

• on medication interfere with muscle contraction

• with known allergy to any drug used in the study